Moustapha Aoula, Andreu Pauline, Gonzalvez François, Fradin Delphine, Tissier Jean-Pierre, Diolez Phillippe, Petit Patrice Xavier
National Center for Scientific Research UMR 8003, Paris City University, SSPIN Neuroscience Institute, Saint-Germain Campus, Paris, Île de France 75006, France.
Department of Genetic and Development, INSERM U567/National Center for Scientific Research UMR 8104, Cochin Institut, Paris 750014, France.
J Biol Methods. 2024 Dec 30;11(4):e99010040. doi: 10.14440/jbm.2024.0055. eCollection 2024.
HA14-1 is a small-molecule, stable B-cell lymphoma 2 (Bcl-2) antagonist that promotes apoptosis in malignant cells through an incompletely-defined mechanism of action. Bcl-2 and related anti-apoptotic proteins, such as B-cell lymphoma-extra-large [Bcl-XL]), are predominantly localized to the outer mitochondrial membrane, where they regulate cell death pathways. However, the notably short half-life of HA14-1 limits its potential therapeutic application. To address this limitation, a more stable analog, ethyl-2-amino-6-phenyl-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (sHA14-1), was developed.
This study investigated the relationship between sHA14-1 and Bcl-2/Bcl-XL. The sHA14-1 molecule acts as a hormetic substance. Therefore, it is crucial to determine whether the hormetic zone corresponds to a putative therapeutic window, that is, the optimal concentration at which sHA14-1 selectively kills cancer cells overexpressing Bcl-2 or Bcl-XL while causing minimal damage to normal cells.
Using classical cell biology and flow cytometry, we examined the main signaling pathways involving Bcl-2 or Bcl-XL, and their modification in the presence of sHA14-1.
We showed that sHA14-1 exerted a dual effect on mitochondria: (i) it sensitized cells to increased permeability, and (ii) it inhibited adenosine diphosphate-stimulated respiration and uncoupled respiration. At relatively low concentrations, sHA14-1 induced mitochondrial swelling, reminiscent of "pore opening" but with distinct characteristics. Over 30 μM, sHA14-1 caused mitochondrial transition depolarization independent of permeability transition and cell death that resembled secondary necrosis (., occurring after maximal mitochondrial permeability) rather than apoptosis. The balance between apoptotic and necrotic cell death induced by sHA14-1 was also evaluated.
Our results suggested that sHA14-1 plays a multifunctional role, involving both mitochondria and the endoplasmic reticulum. Its actions are more complex than its originally intended role in targeting anti-apoptotic Bcl-2 family members, which may complicate its potential application as an anticancer therapy.
HA14 - 1是一种小分子、稳定的B细胞淋巴瘤2(Bcl - 2)拮抗剂,通过一种尚未完全明确的作用机制促进恶性细胞凋亡。Bcl - 2和相关的抗凋亡蛋白,如B细胞淋巴瘤-超大蛋白[Bcl - XL]),主要定位于线粒体外膜,在那里它们调节细胞死亡途径。然而,HA14 - 1显著较短的半衰期限制了其潜在的治疗应用。为了解决这一限制,研发了一种更稳定的类似物,即2 - 氨基-6 - 苯基-4 -(2 - 乙氧基-2 - 氧代乙基)-4H - 色烯-3 - 羧酸乙酯(sHA14 - 1)。
本研究调查了sHA14 - 1与Bcl - 2/Bcl - XL之间的关系。sHA14 - 1分子作为一种应激效应物质。因此,确定应激效应区是否对应于一个假定的治疗窗口至关重要,即sHA14 - 1在该最佳浓度下能选择性杀死过表达Bcl - 2或Bcl - XL的癌细胞,同时对正常细胞造成最小损伤。
使用经典细胞生物学和流式细胞术,我们检测了涉及Bcl - 2或Bcl - XL的主要信号通路,以及在sHA14 - 1存在下它们的变化。
我们表明sHA14 - 1对线粒体产生双重作用:(i)它使细胞对通透性增加敏感,(ii)它抑制二磷酸腺苷刺激的呼吸并使呼吸解偶联。在相对较低浓度下,sHA14 - 1诱导线粒体肿胀,类似于“孔开放”但具有不同特征。超过30μM时,sHA14 - 1导致线粒体跨膜电位去极化,与通透性转换无关,且细胞死亡类似于继发性坏死(即在最大线粒体通透性后发生)而非凋亡。还评估了sHA14 - 1诱导的凋亡和坏死性细胞死亡之间的平衡。
我们的结果表明sHA14 - 1发挥多功能作用,涉及线粒体和内质网。其作用比最初针对抗凋亡Bcl - 2家族成员的预期作用更为复杂,这可能使其作为抗癌疗法的潜在应用变得复杂。